Cogane is an orally bioavailable neurotrophic factor inducer that crosses the blood-brain barrier and shows neuroprotective effects.
The interim results of Cogane show promising activity in preclinical in vitro and in vivo models of ALS.
The study costs are funded through a UK based charitable organisation – Motor Neurone Disease Association.
A study of Cogane in the genetic in vivo model of ALS is ongoing and the study results are expected in Q4 2011.